Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efepoetin alfa - Genexine Biologics

Next Previous
Drug Profile

Efepoetin alfa - Genexine Biologics

Alternative Names: Efesa; Ephepoetin Alpha; EPO-hFC; EPO-hybrid Fc; EPO-hyFc; Erythropoietin biobetter - Genexine; GC-1113; GX-E2; GX-E4; HyPoietin; Long-acting EPO; Recombinant erythropoietin long-acting - Genexine/GC Biopharma

Latest Information Update: 09 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genexine
  • Developer Genexine; PT Kalbe Genexine Biologics
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 09 Dec 2025 Launched for Anaemia in Indonesia (SC) (Genexine pipeline, December 2025)
  • 25 Mar 2025 Genexine completes phase I pharmacokinetics and pharmacodynamics trial (In volunteers) in South Korea (IV, Injection) (NCT06490939)
  • 29 Oct 2024 Genexine initiates enrolment in phase I pharmacokinetics and pharmacodynamics trial (In volunteers) in South Korea (IV, Injection) (NCT06490939)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top